Loader

Open a Trading Account

Register as Guest

Become a Partner

Please fill in your details

Equity

Index Movement
Heat Map
Advance
Declines
Unchange

from research desk

Fundamental

buy

SPAL

call date:08-Nov-2016
Potential gain
19.11 %
Recommended Price(`) : 326.00
CMP(`)388.70
TARGET(`)463.00
STOP LOSS(`)0.00
Trade

Technical

buy

KWALITY

call date:14-Nov-2017
Potential gain
12.11 %
Recommended Price(`) : 100.00
CMP(`)105.25
TARGET(`)118.00
STOP LOSS(`)95.00
view Trade

Market Stats

Stock Comparison

Compare Stocks on Chart & Fundamentals
Stock 1
Stock 2
Compare

NEWS

Unichem gains on concluding sale, transfer of domestic formulations business in India, Nepal
15 Dec 15:27

Unichem Laboratories is currently trading at Rs. 304.05, up by 4.20 points or 1.40% from its previous closing of Rs. 299.85 on the BSE.The scrip opened at Rs. 306.00 and has touched a high and low of Rs. 315.00 and Rs. 301.45 respectively. So far 13198 shares were traded on the counter.The BSE group `B` stock of face value Rs. 2 has touched a 52 week high of Rs. 350.25 on 06-Nov-2017 and a 52 week low of Rs. 234.10 on 11-Aug-2017.Last one week high and low of the scrip stood at Rs. 315.00 and Rs. 295.40 respectively. The current market cap of the company is Rs. 2741.27 crore.The promoters holding in the company stood at 50.06%, while Institutions and Non-Institutions held 17.85% and 32.09% respectively.Unichem Laboratories (Unichem) has completed the sale and transfer of its domestic formulations business in India and Nepal together with the manufacturing facility at Sikkim, on a going concern basis by way of slump sale, to Torrent Pharmaceuticals. This transaction was in pursuance of the definitive binding agreement entered into between Unichem and Torrent on November 3, 2017.Going ahead Unichem will focus attention on all aspects of the international business including finished formulations, API, contract manufacturing and contract research; increase its investments in R&D in the New Chemical and Biological Entities (NCE & NBE), Bio-similars and complex generics and reward shareholders.Unichem is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India and several other markets across the world.

Torrent Pharma rises on the bourses
15 Dec 15:16

Torrent Pharmaceuticals is currently trading at Rs. 1343.75, up by 28.75 points or 2.19% from its previous closing of Rs. 1315.00 on the BSE.The scrip opened at Rs. 1326.40 and has touched a high and low of Rs. 1356.75 and Rs. 1326.40 respectively. So far 2460 shares were traded on the counter.The BSE group `A` stock of face value Rs. 5 has touched a 52 week high of Rs. 1572.10 on 31-Mar-2017 and a 52 week low of Rs. 1143.50 on 29-May-2017.Last one week high and low of the scrip stood at Rs. 1356.75 and Rs. 1300.05 respectively. The current market cap of the company is Rs. 22667.38 crore.The promoters holding in the company stood at 71.25%, while Institutions and Non-Institutions held 18.52% and 10.24% respectively.Torrent Pharmaceuticals (Torrent) has completed acquisition of branded formulation business of Unichem Laboratories (Unichem) for India and Nepal, including its Sikkim manufacturing facility, on a going concern basis by way of slump sale, on December 14, 2017. This transaction was in pursuance of the definitive binding agreement entered into between Torrent and Unichem on November 3, 2017.From today, Torrent begins the integration of the Unichem business following the successful closure of its acquisition. The integration will aim to fuel and support strong growth of the acquired Unichem brands, consolidating speciality reach with a relentless focus on enhancing productivity. The acquisition will accelerate Torrent’s presence in the chronic space especially in the high growth segments of Indian Pharma market like Cardiology, Diabetology and Gastroenterology. Moreover, Unichem brings in an important new platform in Torrent’s sustainable growth strategy by expanding the company’s presence in the OTC segment.Torrent Pharmaceuticals is Flagship Company of the Torrent group, a leader in cardiovascular and central nervous system segments. It also has presence in gastro-intestinal, diabetology, anti-infective and pain management segments.

BHEL moves up on bagging order worth Rs 7,300 crore
15 Dec 14:58

Bharat Heavy Electricals is currently trading at Rs. 89.85, up by 0.20 points or 0.22% from its previous closing of Rs. 89.65 on the BSE.The scrip opened at Rs. 89.90 and has touched a high and low of Rs. 91.80 and Rs. 89.35 respectively. So far 686875 shares were traded on the counter.The BSE group `A` stock of face value Rs. 2 has touched a 52 week high of Rs. 121.83 on 25-Apr-2017 and a 52 week low of Rs. 77.47 on 27-Dec-2016.Last one week high and low of the scrip stood at Rs. 92.65 and Rs. 88.20 respectively. The current market cap of the company is Rs. 32987.53 crore.The promoters holding in the company stood at 63.06%, while Institutions and Non-Institutions held 31.54% and 5.40% respectively.Bharat Heavy Electricals (BHEL) has won an order for setting up a 1,320 MW Supercritical Thermal Power Project (TPP) in Tamil Nadu. Valued at over Rs 7,300 crore, the order for setting up the 2x660 MW Udangudi TPP has been placed on BHEL by Tamil Nadu Generation and Distribution Corporation (TANGEDCO). Significantly, this is the fourth order for supercritical sets finalised in the last three years by TANGEDCO, and all the four orders have been won by BHEL. The previous three orders viz 2x660 MW Ennore SEZ, 1x800 MW North Chennai Supercritical TPP Stage-III and 2x800 MW Uppur TPP were also secured by BHEL on ICB basis, reinforcing its position as the frontrunner in the power generation equipment industry in India. The implementation of the new projects will help foster growth in Tamil Nadu and provide easy access to electricity to the people of the state. At present, BHEL has a significant share of 83% in the state`s coal-based generating capacity and has been a major partner in the power development programme of Tamil Nadu. BHEL is India’s largest engineering and manufacturing company of its kind. It is a power plant equipment manufacturer and operates as an engineering and manufacturing company.

Lupin trades higher on the bourses
15 Dec 14:42

Lupin is currently trading at Rs. 863.60, up by 11.55 points or 1.36% from its previous closing of Rs. 852.05 on the BSE.The scrip opened at Rs. 858.00 and has touched a high and low of Rs. 868.00 and Rs. 855.00 respectively. So far 104410 shares were traded on the counter.The BSE group `A` stock of face value Rs. 2 has touched a 52 week high of Rs. 1572.25 on 06-Feb-2017 and a 52 week low of Rs. 807.00 on 06-Dec-2017.Last one week high and low of the scrip stood at Rs. 868.00 and Rs. 822.50 respectively. The current market cap of the company is Rs. 39090.05 crore.The promoters holding in the company stood at 46.80%, while Institutions and Non-Institutions held 40.05% and 13.14% respectively.Lupin has received final approval for its Tydemy (Drospirenone, Ethinyl Estradiol, and Levomefolate Calcium Tablets, 3 mg/0.03 mg/0.451 mg and Levomefolate Calcium Tablets, 0.451 mg) from the United States Food and Drug Administration (USFDA) to market a generic version of Safyral Tablets of Bayer HealthCare Pharmaceuticals Inc. Drospirenone, Ethinyl Estradiol, and Levomefolate Calcium Tablets, 3 mg/0.03 mg/0.451 mg and Levomefolate Calcium Tablets, 0.451 mg tablets had annual sales of around $22.9 million in the US, as per IMS MAT October 2017.The company’s Tydemy (Drospirenone, Ethinyl Estradiol, and Levomefolate Calcium Tablets, 3 mg/0.03 mg/0.451 mg and Levomefolate Calcium Tablets, 0.451 mg) is the AB rated generic equivalent of Safyral Tablets of Bayer HealthCare Pharmaceuticals Inc. Tydemy is indicated for use by women to prevent pregnancy and to raise folate levels in women who choose to use an oral contraceptive for contraception.Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Gulf Oil Lubricants gains on commencing commercial production at Chennai plant
15 Dec 14:13

Gulf Oil Lubricants India is currently trading at Rs. 990.00, up by 13.65 points or 1.40% from its previous closing of Rs. 976.35 on the BSE.The scrip opened at Rs. 1000.00 and has touched a high and low of Rs. 1000.00 and Rs. 984.60 respectively. So far 217 shares were traded on the counter.The BSE group `B` stock of face value Rs. 2 has touched a 52 week high of Rs. 1098.50 on 01-Dec-2017 and a 52 week low of Rs. 577.00 on 26-Dec-2016.Last one week high and low of the scrip stood at Rs. 1,000.00 and Rs. 955.50 respectively. The current market cap of the company is Rs. 4920.29 crore.The promoters holding in the company stood at 72.88%, while Institutions and Non-Institutions held 14.50% and 12.62% respectively.Gulf Oil Lubricants India has commenced commercial production for manufacturing of lubricants oil at its newly set-up plant at Chennai (Ennore) on December 14, 2017. The installed manufacturing capacity of new plant is 50,000 KL per annum.Gulf Oil Lubricants India is one of the leading private sector players in the lubricant industry & currently the fastest growing lubricant marketer in India.

Markets Today